Risankizumab vs. adalimumab for moderate‐to‐severe plaque psoriasis: a critical appraisal

Ali Al-Janabi, Richard Warren

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with moderate-to-severe plaque psoriasis have greatly benefited from the availability of biologics. However, treatment-selection can be challenging and it is important that with growing numbers of biologics available, head-to-head trials comparing efficacy and safety outcomes are undertaken. Most head-to-head trials comparing newer classes of biologics to tumour necrosis factor-α inhibitors have compared with etanercept, which is less commonly used than adalimumab.
Original languageEnglish
Pages (from-to)220-221
JournalBritish Journal of Dermatology
Volume183
Issue number2
Early online date13 Feb 2020
DOIs
Publication statusPublished - 2 Aug 2020

Fingerprint

Dive into the research topics of 'Risankizumab vs. adalimumab for moderate‐to‐severe plaque psoriasis: a critical appraisal'. Together they form a unique fingerprint.

Cite this